SEC Form SC 13G/A filed by Amgen Inc. (Amendment)
$AMGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2026 | Buy → Hold | Erste Group | |
| 4/21/2026 | $366.00 | Hold | Canaccord Genuity |
| 3/10/2026 | $350.00 | Hold | Jefferies |
| 2/20/2026 | $185.00 | Equal Weight | Barclays |
| 1/20/2026 | $335.00 | Outperform → Mkt Perform | Bernstein |
| 1/7/2026 | $380.00 | Buy | UBS |
| 12/5/2025 | Hold → Buy | Erste Group | |
| 11/24/2025 | $318.00 | Hold | Truist |
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
4 - AMGEN INC (0000318154) (Issuer)
Erste Group downgraded Amgen from Buy to Hold
Canaccord Genuity initiated coverage of Amgen with a rating of Hold and set a new price target of $366.00
Jefferies initiated coverage of Amgen with a rating of Hold and set a new price target of $350.00
Submission status for AMGEN INC's drug WEZLANA (SUPPL-6) with active ingredient USTEKINUMAB-AUUB has changed to 'Approval' on 05/12/2026. Application Category: BLA, Application Number: 761331, Application Classification:
Submission status for AMGEN INC's drug WEZLANA (SUPPL-6) with active ingredient USTEKINUMAB-AUUB has changed to 'Approval' on 05/12/2026. Application Category: BLA, Application Number: 761285, Application Classification:
Submission status for AMGEN INC's drug WEZLANA (SUPPL-6) with active ingredient USTEKINUMAB-AUUB has changed to 'Approval' on 05/13/2026. Application Category: BLA, Application Number: 761285, Application Classification:
4 - AMGEN INC (0000318154) (Reporting)
8-K - AMGEN INC (0000318154) (Filer)
8-K - AMGEN INC (0000318154) (Filer)
SCHEDULE 13G - AMGEN INC (0000318154) (Subject)
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA® in IgG4-RD Real-World Evidence Supports TAVNEOS® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated VasculitisTHOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.New data from the Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) provide insights into the biology of immunoglobulin G4-related disease (IgG4-RD),1 while additional
THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, Narimon Honarpour, senior vice president of global development at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.The webcast, as with other selected presentations regarding developments in Amgen's business given by management at
LOS ANGELES, May 27, 2026 /PRNewswire/ -- Ember LifeSciences, Inc., ("Ember") a leading provider of revolutionary cold chain technology, today announced strategic investments from Amgen Ventures, the corporate venture arm of Amgen (NASDAQ: AMGN) a leading global biotechnology company and TDF Ventures, a venture capital firm focused on early-stage investments in enterprise-focused technology sectors. The investments follow Ember LifeSciences' previously announced Series A financing led by Sea Court Capital and comes as the company announces full commercial availability of the Emb
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13G/A - AMGEN INC (0000318154) (Subject)
SC 13D - AMGEN INC (0000318154) (Filed by)
Thomas Dittrich Returning to Amgen as CFO THOUSAND OAKS, Calif., May 19, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of Peter Griffith, who has served as the company's executive vice president and chief financial officer since 2020. The company also announced that Thomas Dittrich will return to Amgen as executive vice president on July 1 and succeed Griffith as chief financial officer effective September 1, 2026."We are grateful to Peter for his leadership and lasting impact on the company," said Robert A. Bradway, chairman and chief executive officer at Amgen. "Peter has helped position Amgen to deliver attractive long-term growth and expand our ability to serve
Organizational Changes Further Emphasize Integration of Biology and TechnologyTHOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026. Reese joined Amgen in 2005 as a clinical development leader in oncology and later served as executive vice president of Research and Development (R&D) from 2018 to 2023. During his tenure, he led approvals of numerous innovative medicines and biosimilars, advanced a robust pipeline of potential new therapies and strengthened discovery research capabilities. As inaugural chief technology officer, Reese encoura
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolioBrings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appoi
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA® in IgG4-RD Real-World Evidence Supports TAVNEOS® Efficacy and Safety Profile with Reduced Steroid Use in ANCA-Associated VasculitisTHOUSAND OAKS, Calif., June 3, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data across rare autoimmune and inflammatory diseases at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place from June 3-6 in London.New data from the Phase 3 MITIGATE trial of UPLIZNA® (inebilizumab) provide insights into the biology of immunoglobulin G4-related disease (IgG4-RD),1 while additional
Investment Strengthens American Manufacturing, Supply Chain Resilience and Next-Generation TechnologyTHOUSAND OAKS, Calif., May 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients."Amgen has been a leader in U.S. biomanufacturing for decades, and this expansion reflects our continued commitment to American manufacturing," said Robert A. Bradway, chairman and chief executive officer at Amgen. "By growing our operations in Puerto Rico, we are ensuring patients have acc
THOUSAND OAKS, Calif., April 30, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026."Our first quarter results demonstrate the strength of our business, with 16 brands achieving double-digit growth, enabling us to grow through expected patent expirations and increased competition. With a new wave of molecules progressing in Phase 3 clinical development, we're confident in our ability to deliver attractive long-term growth," said Robert A. Bradway, chairman and chief executive officer.Key results include:For the first quarter, total revenues increased 6% to $8.6 billion in comparison to the first quarter of 2025.Product sales grew 4%, driv